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Abstract The growth hormone–insulin-like growth factor I
(IGF-I) axis is an important physiological regulator muscle
for development. Although there is evidence that aging
muscle retains the ability to synthesize IGF-I, there is also
evidence that aging may be associated with attenuation of
the ability of exercise to induce an isoform of IGF-I that
promotes satellite cell proliferation. However, it is clear that
overexpression of IGF-I in the muscle can protect against
age-related sarcopenia. Strength training appears to be the
intervention of choice for the prevention and treatment of
sarcopenia. IGF-I has been implicated in the loss of the
muscle with age, and IGF-I expression levels change as a
consequence of strength training in older adults. However,
it seems that advancing age, rather than declining serum
levels of IGF-I, appears to be a major determinant of life-
time changes in body composition in women and men. We
concluded that resistive exercise is a significant determinant
of muscle mass and function. Elevated levels of IGF-I have
been found in physically active compared to sedentary
individuals. Recent work suggests that IGF-I as a mediator
plays an important role in muscle hypertrophy and
angiogenesis, both of which characterize the anabolic
adaptation of muscles to exercise.
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Human muscle strength declines at the rate of 12–14% per
decade after the age of 50 years [66, 68]. This loss of
strength with age is due to many factors but is primarily
attributed to a loss of muscle mass bringing to sarcopenia
[30, 86]. Sarcopenia is related to a loss of functional
abilities [82], dependency [83], increased risk of falls,
fractures [5, 67], and decreased bone mineral density [94].
Thus, sarcopenia has negative consequences for the health
status and functional abilities of older adults. Recent
research has addressed the hypothesis that growth hormone
(GH) and insulin-like growth factor I (IGF-I) have an
anabolic effect in adults, including the elderly. These
hormones stimulate whole-body and muscle protein syn-
thesis, at least under some conditions. Serum IGF-I levels
as well as GH secretion decline with advancing age [26, 92,
93]. The declining activity of the GH–IGF-I axis with
advancing age may contribute to the decrease in lean body
mass and the increase in mass of adipose tissue that occur
with aging [17, 44, 100].
Mechanisms underlying age-associated change in body
composition such as an increase in body fat and a decrease in
bone mass are not fully understood. Decrease in GH secretion
and serum IGF-I levels with aging may have some impact on
these processes. IGF-I is predominantly synthesized in the
liver, and serum levels of IGF-I are tightly regulated by GH
release [79] and are indicated to reflect the integrated
24-h secretion of GH [15]. IGF-I is a trophic factor required
for the proliferation of myoblasts, the proliferation of
myogenic differentiation, and subsequent growth and hyper-
trophy of myofibers [27]. IGF-I has been identified as a
potent regulator of gene expression in the skeletal muscle.
Excitation–contraction uncoupling has been identified as a
mechanism underlying sarcopenia in the skeletal muscle in
aging mammals. The basic mechanism for excitation–
contraction uncoupling is a larger number of ryanodine
receptors uncoupled to dihydropyridine receptors [17]. In
addition to effects on muscle development, IGF-I facilitates
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skeletal muscle dihydropyridine activity via tyrosine kinase–
protein kinase C-dependent phosphorylation [18]. It has also
shown that IGF-I-dependent dihydropyridine modulation is
impaired in aging skeletal muscles [87], which may explain,
at least partially, the decline in muscle force with aging [79].
It has been established that high levels of GH and IGF-I
increase body weight, bolster bone and muscle mass, and
enhance immune function [64]. These hormones also
modulate the onset of puberty and generally increase
reproductive fitness. Furthermore, administration of GH or
IGF-I to aged animals restores many of the deficits
associated with age, including declines in immune function,
bone mass, and skin thickness [16]. In addition to the
attenuation of age-related physical deficits, administration of
IGF-I to rodents prevents the development of age-related
cognitive impairments [71]. These findings and others not
detailed in this review provide evidence that the deficiency
in GH and IGF-I contributes to the aged phenotype.
As described earlier in this review, GH and IGF-I are
potent anabolic hormones that increase cellular metabolism
and as a result enhance the function of numerous tissues.
This effect is particularly important during development,
when GH and IGF-I levels are high, and during aging,
when these hormones’ levels are low. It was propose that
the GH–IGF-I-induced increase in metabolic activity results
in increased glucose utilization, increased oxygen con-
sumption, and increased oxidative stress [69].
In middle and late adulthood, all people experience a
series of progressive alterations in body composition [93].
The contraction in lean body mass reflects atrophic
processes in the liver, kidney, spleen, skin, bone, and
skeletal muscle because of slower muscle protein synthesis.
These structural changes have been considered unavoidable
results of aging. It has recently been proposed, however,
that reduced availability of GH in late adulthood may
contribute to such changes [74, 93]. This proposal is based
on two lines of evidence. First, after about the age of 30, the
secretion of GH by the pituitary gland tends to decline [25,
92, 93]. Second, GH secretion can be measured indirectly by
measuring the plasma concentration of IGF-I (also known as
somatomedin C), which is produced and released in response
to GH [14]. Because GH is secreted in pulses, mostly during
the early hours of sleep, it is difficult to measure the
24-h secretion of the substance directly. There is little diurnal
variation in the plasma IGF-I concentration, and measure-
ments of it are therefore a convenient indicator of GH
secretion [14]. Therefore, the atrophy of the lean body mass,
its component organs, and the enlargement mass of adipose
tissue, which are characteristic of the elderly, result at least in
part from diminished secretion of GH [74, 93]. If so, the age-
related changes in body composition may be correctable in
part by the administration of human GH, now readily
available as a biosynthetic product [50].
In healthy individuals, the anabolic GH–IGF-I axis
maintains muscle mass by suppressing protein degradation,
increasing amino acid uptake, and stimulating protein
synthesis [89]. The bioavailability of IGF-I is dependent
upon circulating IGF-I and IGF-I-binding protein (IGFBP)
levels (fibroblast growth factor [FGF] 2). Like IGF-I, FGF-2
is ubiquitously distributed and is one of the most potent
mitogens for myoblasts and plays a critical role in myo-
genesis and capillary angiogenesis during muscle develop-
ment [4]. Furthermore, stress-induced muscle remodeling
and repair after extensive pathological injuries are believed
to be activated by FGF-2. It is also suggested that low levels
of serum IGF-I may be involved in the progression of
dementia in the oldest of the old [104]. An age-associated
decline in serum IGF-I levels exist even in extremely old
age, without being associated with lower body mass index,
hypoalbuminemia, or poor functional status.
Less than 5% of the healthy men 20 to 40 years old have
plasma IGF-I values of less than 350 U l−1, but the values
are below this figure in 30% of the healthy men more than
60 [92]. Likewise, the nocturnal pulses of GH secretion
become smaller or disappear with advanced age. If the
plasma concentration of IGF-I falls below 350 U l−1 in
older adults, no spontaneous circulating pulses of GH can
be detected by currently available radioimmunoassay
methods [92]. The concomitant decline in plasma concen-
trations of both hormones supports the view that the
decrease in IGF-I results from diminished GH secretion
[26, 92]. Second, diminished secretion of GH is accompa-
nied not only by a fall in the plasma IGF-I concentration
but also by atrophy of the lean body mass and expansion of
the mass of adipose tissue [93]. It may not be relevant to
use the serum IGF-I level as an indicator of GH release in
centenarians, but instead, the IGF-I level appeared to reflect
its short-term nutritional status as a rapid turnover protein.
Further longitudinal studies, including assessment of
IGFBPs and the association of IGF-I with dementia, should
be conducted in the future.
Physiological age-related muscle loss and weakness is
referred to as sarcopenia. The etiology is multifactorial and
not fully understood. However, during aging, there is
evidence of declining activity of the GH–IGF-I axis, which
is mainly dependent on age-related variations in the
hypothalamic control of somatotroph function (somato-
pause). It has been reported that in older individuals, there
is reduced GH production and attenuated IGF-I response to
high-resistance exercise [39]. Furthermore, previous studies
have demonstrated a delayed response to FGF-2 with aging
satellite cells, most probably because of delayed expression
of FGF-2 receptors and delayed binding of FGF-2 to the
receptors [9].
The results of cross-sectional studies suggest that
sarcopenia is a major determinant of aging-associated
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decrements in strength [31, 84]. Sarcopenia involves
significant alterations in the architecture of human muscles
that stem from a loss of some myofibers and the remodeling
of those that remain [77, 101]. It has been suggested that
sarcopenia results from both a loss of myofibers and a
decrease in type II fiber size [65]. In humans, age-related
myofiber loss and myofiber atrophy generally involve type
IIa and IIb fibers, with a greater impact seen in the IIb
fibers [65, 76].
From results of epidemiological studies and interven-
tional trials using recombinant human GH, serum IGF-I
levels have shown a positive association with muscle
strength, lean body mass [95, 96], and physical activity
[62], and they have shown a negative correlation with body
mass index and the body fat index [81, 93]. However, in the
elderly population, serum IGF-I levels have been reported
to have no association with body mass index, body fat, or
lean body mass, but they have been significantly correlated
with nutritional parameters and liver function [41]. More-
over, recent epidemiologic studies demonstrated that low
serum IGF-I levels may be associated with increased
cardiovascular risk [48] and cognitive impairment [3] in
the elderly population. These data suggest that IGF-I values
in elderly persons may not represent their GH activities and
determinants of serum IGF-I levels may differ from middle-
aged individuals.
IGF-I response to either acute or chronic physical
activity remains unclear [59]. Based on several studies
done in healthy young adults, there is an increase in
circulating IGF-I in response to different types of exercise,
either aerobic, resistance, or heavy ergometer cycling [10,
54, 58, 91], while exercise training improves local IGF-I
expression without significant changes of systemic param-
eters of the GH–IGF-I axis. These findings indicate that
exercise training has the therapeutic potential to attenuate
peripheral skeletal muscle alterations in particular with
respect to local IGF-I expression in patients with moderate
cardiac heart failure [38].
Growing evidence suggest that IGF-I and FGF-2 play an
important role in exercise-induced muscle hypertrophy and
angiogenesis. Importantly, recent work suggests the possi-
ble synergism of local FGF-2 and circulating IGF-I in the
regulation of the anabolic adaptation of muscles to exercise
[103]. The mechanisms that mediate the functional adapta-
tion of the skeletal muscle appear to reside, primarily,
within the impacted muscle. This circumstance accounts for
the specific adaptation of effected muscles. The skeletal
muscle loading experienced as part of occupational and
athletic activities often includes periods of loaded muscle
shortening and lengthening as well as periods during which
muscles are activated but no external length changes occur
(isometric loading). The relative contribution of these three
modes of loading to the processes that stimulate muscle
adaptation is of great interest in the area of programmed
resistance training. It is well known that resistance training
paradigms that include sufficient intensity, frequency, and
duration can induce skeletal muscle adaptations that include
compensatory hypertrophy [57]. It has also become com-
mon for such programs to emphasize one particular training
mode (e.g., lengthening, shortening, or isometric). Training
programs that have employed relatively pure shortening,
lengthening, or isometric loading have demonstrated that
each of these three modes of loading can stimulate muscle
adaptations, including hypertrophy, and strength gains [19,
32, 33, 42, 45, 51, 53, 60, 73, 75, 102, 105].
Muscle mass is arguably the most important determinant
of functional capabilities and as such is an important
consideration in a number of occupational and clinical
settings. Load-bearing or resistance-type exercise is the
primary method for the maintenance of, increase in, or
recovery of muscle mass. This can be particularly important
in settings where muscle atrophy is a risk such as bed rest
or spaceflight [47]. It is well established that exercise is a
significant determinant of muscle mass and function.
As mentioned previously, the GH–IGF-I axis and FGF-2
are important physiological regulators of fetal and postnatal
growth and development [48]. Physical exercise has a
significant impact on the GH–IGF-I axis. However, data
from studies evaluating IGF-I response to exercise are
controversial. Findings indicate that although both peak
aerobic capacity and circulating IGF-I levels decline with
age, aerobic capacity is not independently related to
circulating IGF-I in healthy men and women across the
adult lifespan [43].
Decline in muscle strength and muscle mass with age is
well documented [50, 51] and is associated with a
deterioration of health status and functional abilities [5,
47]. Strength training is thought to be an effective
intervention against sarcopenia because it increases muscle
strength and muscle mass in the elderly [22, 23, 29, 37, 46,
98]. Muscle mass and neuromuscular factors contribute to
losses in strength with age [52, 63] and gains in strength
with strength training [34, 37].
While some studies have demonstrated no change in
circulating IGF-I levels, in many others, exercise induced a
transient increase in IGF-I levels resulting from acute
release of IGF-I from its binding proteins [59]. Further-
more, IGF-I response depends on exercise type, intensity,
and duration as well as training status [88, 90]. However,
Bermon et al. [8] investigated the effects of an acute bout of
exercise on total and free IGF-I and IGFBP-3 plasma
concentrations, 32 healthy elderly subjects (67–80 years, 16
men) performed a strength test. Subjects were then
randomly assigned to habitual physical activity or to an
8-week strength-training program. After 8 weeks, both
sedentary and trained groups underwent blood samplings
Eur Rev Aging Phys Act (2007) 4:77–84 79
under the abovementioned conditions. The exercising group
showed increased total and free IGF-I concentrations
immediately (+17.7 and +93.8%, respectively) and 6 h
(+7.5 and +31.2%, respectively) after the test, whereas no
significant changes in IGFBP-3 concentrations were ob-
served in either exercising or resting control groups.
Strength training induced no significant changes in baseline
IGF-I and IGFBP-3 concentrations. Trained and sedentary
groups showed a similar hormonal response pattern to the
strength test, which consisted of increased total and free
IGF-I concentrations, indicating that strength exercise can
induce an early and sustained IGF-I release, in elderly
subjects, regardless of their training status. Resistance
exercise is known to dramatically increase protein synthe-
sis, accretion, and muscle hypertrophy [2, 21]. Whereas
Adams et al. [2, 28] reported that muscle IGF-I is elevated
early in the time course of myogenesis in overloaded
skeletal muscle, the precise role that IGF-I plays in
mediating this process (systemic vs local) is still poorly
defined [21].
There are not many studies on IGF-I response to exercise
in older age during which the activity of the GH–IGF-I axes
declines. Specifically, the response of older individuals to
acute all-out anaerobic exercise has not yet been investigat-
ed. In the few studies conducted to date in older individuals,
controversial results have been obtained [36, 85, 97]. Most
studies dealing with the acute response of IGF-I to
resistance exercise have shown no change in serum IGF-I
level [11, 55]. The chronic adaptation of circulating IGF-I
in response to resistive training is controversial as well.
While a few studies have reported no change in resting
levels of IGF-I after short-term resistance training [40, 56,
99], other studies have shown elevations in IGF-I during
short/long-term resistance-training programs [88, 91], par-
ticularly during high-volume training [61, 72]. Furthermore,
IGF-I increased after endurance type physical training [94]
and triathlon training [70]. The mechanism of this response
has not been fully resolved and likely involves both
increased skeletal muscle IGF-I release and increased
clearance rate of IGF-I from IGFBP [59].
Anaerobic power is characterized by exposing subjects
to a very high degree of sudden strenuous all-out exercise.
Little data are available on changes in the levels of IGF-I and
FGF-2 after sudden strenuous anaerobic exercise in healthy
older subjects. Furthermore, the effect of fitness level on
these responses has not been studied yet. It has been
hypothesized [4] that aerobically trained older men would
manifest greater alterations in serum IGF-I and FGF-2 levels
after the Wingate anaerobic test, than the untrained men.
When evaluating the effect of fitness level on IGF-I and
FGF-2 responses after all-out anaerobic exercise in healthy
older men, suggested fitness level dependent alterations in
the response of older individuals to the Wingate anaerobic
exercise regarding the levels of IGF-I and FGF-2. The
study demonstrates that trained compared to untrained older
men had lower pre-exercise serum levels of IGF-I and
higher pre-exercise FGF-2 levels. After the Wingate
anaerobic exercise, there was a transient elevation in the
level of IGF-I in both higher-fit and lower-fit individuals.
However, IGF-I elevation was significant only in the
trained individuals. Contrary to IGF-I, postexercise levels
of FGF-2 decreased dramatically to almost undetectable
levels in both groups and remained low for 50 min into
recovery. The data of the study of Amir et al. [4] suggest
that during aging, fitness level is an important determinant
of growth factors responses to exercise.
By modulating the anabolic effects of growth factors, the
fitness level may have positive effects on aging-associated
skeletal muscle loss. This suggests that despite a decline in
the GH–IGF-I axis in older age, IGF-I response to acute
exercise improves among better-trained subjects. The
exercise-induced anabolic adaptations of skeletal muscle
are mostly attributed to IGF-I. Given that IGF-I regulation
is involved in aging-associated sarcopenia and that anaer-
obic muscle activity is represented in many daily life
activities of the elderly, these results highlight the clinical
significance of IGF-I regulation during aging and further
support the notion that exercise training especially for older
individuals can be beneficial.
Surprisingly, Amir et al. [4] have suggested that at rest,
circulating IGF-I in the trained were lower by 17%
compared to the untrained older individuals. The discrep-
ancy between higher levels of IGF-I in healthy young after
2 weeks of strenuous aerobic training [94] and this data
showing lower levels of IGF-I in trained compared to
untrained older individuals might be explained by the
finding of higher IGFBP-1 levels in older age [7]. Unlike
IGF-I response, pre-exercise FGF-2 was 14% higher in the
trained compared to the untrained older individuals and
decreased dramatically (75% reduction in the trained group
and 93% reduction in the untrained group), in response to
the all-out anaerobic exercise, remaining low for at least
50 min into recovery. Similar results have been obtained by
Elyakim et al. [20, 78], who found a significant reduction in
circulating FGF-2 in healthy young individuals after a
single-wrist flexion exercise. Elyakim et al. [20] hypothe-
sized that exercise promotes a marked reduction in
circulating FGF-2 by inducing increased binding of FGF-
2 to endothelial and muscle cells receptors resulting in
redistribution and local capture. However, the effect of
exercise training was evaluated in none of these studies.
Previous studies employing either knee-extensor ergometer
training or intense intermittent endurance training have
analyzed the adaptation of human skeletal muscle to
exercise training at the transcriptional level. Because there
was a slight or no change in the level of skeletal muscle
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FGF-2 messenger ribonucleic acid [49], increased synthesis
does not seem to be the mechanism responsible for the
elevation in pre-exercise circulating FGF-2. However, in
vitro studies on differentiated human skeletal muscle
cultures have demonstrated that mechanical load induces
sarcoplasmic wounding and FGF-2 release from myofibers
with a linear correlation between the degree of mechanical
load and the amount of myofiber wounding and FGF-2
release [12, 13]. In light of these results, it is possible that
prolonged resistive training imitates mechanical load by
causing myofiber damage and FGF-2 release into circula-
tion. The resulting increase in circulating FGF-2 might be
an important compensatory mechanism during aging, in
which the anabolic effects of FGF-2 are reduced by
decreased binding affinity and by the delayed expression
of local FGF-2 receptors [9].
It may be speculated that the changes in IGF-I and FGF-2
may have positive anabolic effects on the induction of
muscle and capillary growth, resulting in muscle hypertro-
phy and angiogenesis. Thus, the fitness-induced alteration in
IGF-I and FGF-2 levels may counteract the process of
skeletal muscle loss, by modulating their positive anabolic
effects, on skeletal muscle. This may have clinical implica-
tions during aging in which the declined activity of growth
factors is a major determinant of the loss of muscle strength
and function. Therefore, during aging, the fitness level can
alter circulating levels of IGF-I and FGF-2 and can affect the
response of both mediators to all-out anaerobic, resistive,
and aerobic exercises. Future studies to elucidate the
mechanisms behind these changes are desirable.
Conclusions
Exercise induce increases in IGF-I, IGF-I receptors, and
IGF-I-activated signaling pathways. Although there is
evidence that the aging muscle retains the ability to
synthesize IGF-I, there is also evidence that aging may be
associated with attenuation of the ability of exercise to
induce an isoform of IGF-I that promotes satellite cell
proliferation. Moreover, the aging muscle may be resistant
to IGF-I, an effect that is reversed by exercise. However, it
is clear that the overexpression of IGF-I in the muscle can
protect against age-related sarcopenia [1]. Strength training
appears to be the intervention of choice for the prevention
and treatment of sarcopenia, based on efficacy and safety
concerns with other interventions [6, 35]. IGF-I has been
implicated in the loss of muscle with age [35], and IGF-I
expression levels change as a consequence of strength
training in older adults [24]. The literature has shown that
in older adults, carriers of the 192 allele at the IGF1 locus
have greater strength gains than noncarriers with strength
training. However, it seems that advancing age, rather than
declining serum levels of IGF-I, appears to be a major
determinant of life-time changes in body composition in
women and men [80].
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